NASDAQ:FULC Fulcrum Therapeutics Q2 2026 Earnings Results & Report $3.77 +0.02 (+0.53%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$3.77 0.00 (0.00%) As of 10/9/2026 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Fulcrum Therapeutics missed analyst earnings expectations in its Q2 2026 results, released July 30, 2026. The company reported EPS of -$0.34 versus the -$0.2433 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateJuly 30, 2026TimeBefore Market OpensConference Call7:00 AM ET Fulcrum Therapeutics EPS ResultsActual EPS-$0.34Consensus EPS -$0.2433Beat/MissMissed by -$0.0967One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersFulcrum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsFulcrum Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, October 28, 2026 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Fulcrum Therapeutics Q2 2026 Earnings FAQ Did Fulcrum Therapeutics beat earnings estimates for Q2 2026? Fulcrum Therapeutics (NASDAQ:FULC) reported earnings of -$0.34 per share for Q2 2026, missing the consensus estimate of -$0.2433. The report was announced on Thursday, July 30, 2026. When is Fulcrum Therapeutics' next earnings date? Fulcrum Therapeutics' next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Fulcrum Therapeutics on the company's earnings history page. Fulcrum Therapeutics Earnings HeadlinesKaplan Fox is Investigating Whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Made Misleading Statements to Investors1 hour ago | theglobeandmail.comBiorestorative Therapies (NASDAQ:BRTX) and Fulcrum Therapeutics (NASDAQ:FULC) Financial ReviewOctober 8 at 3:58 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 10 at 1:00 AM | Chaikin Analytics (Ad)Kaplan Fox Alerts Investors: Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is Under Investigation for Potential Securities Law ViolationsOctober 5, 2026 | theglobeandmail.comFulcrum Therapeutics consensus price target raised 11.22% to $7.75October 2, 2026 | msn.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)September 23, 2026 | globenewswire.comSee More Fulcrum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Fulcrum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulcrum Therapeutics and other key companies, straight to your email. Email Address About Fulcrum TherapeuticsFulcrum Therapeutics (NASDAQ:FULC) is a clinical-stage biopharmaceutical company focused on developing medicines for genetically defined diseases. The company uses its biology and drug-discovery platform to identify molecular targets that can alter gene expression and address the underlying causes of serious disorders. Fulcrum’s lead investigational program has been losmapimod, a small-molecule p38 alpha and beta mitogen-activated protein kinase inhibitor studied as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD), a rare and progressive muscle disease. The company has also evaluated other targeted drug candidates for diseases including cancer and hematologic conditions, although programs and development priorities may change as clinical data become available. Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum serves patients and healthcare markets through its research and clinical-development activities, primarily in the United States and through global clinical studies. The company is led by Robert J. Gould, Ph.D., who has served as president and chief executive officer and as a member of the board of directors.View Fulcrum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
